Clinical Trial

A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity

Study acronym: HF-POLARIS
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study is being done to look at the safety and effect of NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction (HFpEF) or Heart Failure with mildly reduced Ejection Fraction (HFmrEF) and excess body weight when compared to placebo. The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have HFpEF or HFmrEF and excess body weight. Participants will get NNC0487-0111 or placebo by injection once a week. Which treatment participants get is decided by chance. NNC0487-0111 is a new medicine that doctors cannot prescribe yet, but it has been tested in people before.
Protocol Amendment History 2 changes
critical Recruitment opened 2026-07-01
notable Trial sites expanded: 825 -> 838 locations 2026-07-01
Trial Details
NCT Number NCT07567001
Lead Sponsor Novo Nordisk A/S
Conditions Obesity, Heart Failure
Enrollment 5,610 participants
Start Date 2026-05-11
Primary Completion 2029-07-23 (estimated)
Study Completion 2029-08-15 (estimated)
Updated on ClinicalTrials.gov 2026-07-15